Once again, Novo's semaglu­tide shows car­dio­vas­cu­lar ben­e­fit, weight loss — this time in adults with heart fail­ure

No­vo Nordisk’s GLP-1 We­govy has shown car­dio­vas­cu­lar ben­e­fit again, this time in the Phase III STEP HF­pEF tri­al, on top of the ex­pect­ed weight loss, the com­pa­ny an­nounced at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy (ESC) Con­gress to­day.

Against place­bo, 2.4 mg of We­govy (semaglu­tide) showed “large” re­duc­tions in heart fail­ure-re­lat­ed symp­toms and phys­i­cal lim­i­ta­tions, as well as im­prove­ments in ex­er­cise func­tion and weight loss in adults with heart fail­ure with pre­served ejec­tion frac­tion (HF­pEF) and obe­si­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER